Genomic Vision Announces the Pursuit of Its Partnership With Sanofi

Genomic Vision(the “Company” – FR0011799907 – GV), a biotechnology company that develops tools and services dedicated to the analysis and control of changes in the genome, today announces that they have successfully completed work package one of a three-part research agreement for the genetic characterization of Sanofi cell banks.

In 2019 Genomic Vision started the first part of a partnership with Sanofi Genzyme (the specialty care global business unit of Sanofi), to characterize transformed cell lines for bio-production and to compare proprietary molecular combing technology with other laboratory methods

The results obtained in this first milestone, consolidate Genomic Vision’s working hypothesis and paved the way to a better understanding of the genetic characterization of transformed cell lines.

Molecular combing with the FiberVision® product lines provide single molecule visual output of transgene integration patterns with high sensitivity and quantitative results, without amplification bias.

This has the power to precisely monitor the quality of cell lines and assess their stability throughout the manufacturing process, an essential step in the development and production of numerous biological products including viral particles, recombinant therapeutic proteins, monoclonal antibodies as well as contributing to vaccine production.

In parallel, Genomic Vision, among other industrial companies, continues working with the NIST (National Institute of Standards and Technology) consortium to develop quality control tools to be used in genome editing based therapies.

Dominique Remy-Renou, CEO of Genomic Vision, added: With resolution, visualization and sensitivity being key requirements for genetic stability and clonality testing, molecular combing is poised to help create a new benchmark for bioproduction and cell line manufacturing. We are satisfied to complete successfully this first milestone and are confident for the next ongoing work. The engagement with Sanofi Genzyme serves as a proof point in how Genomic Vision can expand utility of molecular combing in high growth markets.

For more such updates and perspectives around Digital Innovation, IoT, Data Infrastructure, AI & Cybsercurity, go to

Related posts

Tempus signs agreement with the United States Department of VA NPOP

Business Wire

Genomic Medicine Company Sangamo Therapeutics Appoints New CFO

Business Wire

High-throughput Single-cell DNA Leader Names Yan Zhang as New CEO

PR Newswire